KRAS and neoplasm: Especially in second line therapy of CRC, with median times to progression of a only a few months, it is unlikely a single cell acquiring a KRAS mutation or even a pre-existing clone could become a substantive portion of a tumor that even at 2 cm in diameter has approximately 8 billion cells.